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Abstract
There is increased interest in the contribution of secreted phospholipase A2 (sPLA2) enzymes to neurodegenerative
diseases. Systemic treatment with the nonapeptide CHEC-9, a broad spectrum uncompetitive inhibitor of sPLA2, has been
shown previously to inhibit neuron death and aspects of the inflammatory response in several models of
neurodegeneration. A persistent question in studies of sPLA2 inhibitors, as for several other anti-inflammatory and
neuroprotective compounds, is whether the cell protection is direct or due to slowing of the toxic aspects of the
inflammatory response. To further explore this issue, we developed assays using SY5Y (neuronal cells) and HL-60
(monocytes) cell lines and examined the effects of sPLA2 inhibition on these homogeneous cell types in vitro. We found that
the peptide inhibited sPLA2 enzyme activity in both SY5Y and HL-60 cultures. This inhibition provided direct protection to
SY5Y neuronal cells and their processes in response to several forms of stress including exposure to conditioned medium
from HL-60 cells. In cultures of HL-60 cells, sPLA2 inhibition had no effect on survival of the cells but attenuated their
differentiation into macrophages, with regard to process development, phagocytic ability, and the expression of
differentiation marker CD36, as well as the secretion of proinflammatory cytokines TNF-a and IL-6. These results suggest
that sPLA2 enzyme activity organizes a cascade of changes comprising both cell degeneration and inflammation, processes
that could theoretically operate independently during neurodegenerative conditions. The effectiveness of sPLA2 inhibitor
CHEC-9 may be due to its ability to affect both processes in isolation. Testing potential anti-inflammatory/neuroprotective
compounds with these human cell lines and their conditioned media may provide a useful screening tool prior to in vivo
therapeutic applications.
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Introduction
Secreted phospholipases A2 (sPLA2) are several closely related
enzymes with molecular masses of 13–20 kDa, belonging to
a growing family of PLA2 enzymes (see review [1]). PLA2 family
catalyzes the hydrolysis of glycerophospholipids at a single A2
bond, producing a free fatty acid and a lysophospholipid. The
excessive hydrolysis of membrane phospholipids by activated
sPLA2s can lead to the alteration of membrane function which can
eventually lead to the functional failure of the membrane and cell
death [2,3]. Furthermore, the free fatty acids and lysophospholipid
products of hydrolysis are precursors for bioactive pro-inflamma-
tory mediators such as eicosanoids and platelet-activating factor
(PAF). The sPLA2s in particular are attractive therapeutic targets
because of their accessibility in the circulation and the fact that
high levels of systemic enzyme activity characterize and contribute
to most inflammatory disorders (see reviews [4,5]), including many
neurodegenerative diseases [6–8]. Recent experimental studies
support this suggestion demonstrating sPLA2 are involved in
nervous system trauma and autoimmune disorders [6,9–11].
CHEC-9(CHEASAAQC) is a potent uncompetitive sPLA2
inhibitor that has been identified in our lab as an internal fragment
of the survival promoting, anti-inflammatory polypeptide DSEP/
Dermcidin/PIF [12–14]. CHEC-9 is considered ‘‘broad-spec-
trum’’ because it inhibits the diverse enzyme activities in the
plasma of rats and humans (dominated by groups IIA and X
sPLA2s), and inhibits the purified enzymes in groups I and III
[9,10,14]. Since CHEC-9 is an uncompetitive inhibitor, it binds
the enzyme substrate complex, so rather than strict sPLA2 isotype
specificity, the inhibitor may prefer certain enzyme-substrate
combinations [9]. Importantly, the anti-inflammatory and neuro-
protective effects of sPLA2 inhibition by CHEC-9 have been
documented for several in vivo models. For example, one sub-
cutaneous injection of CHEC-9, 30–40 min after cerebral cortex
lesions inhibited the appearance and activation of macrophages/
microglia and protected cortical neurons [15]. Similar effects have
now been reported for spinal cord and traumatic brain injury
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a multiple sclerosis model, systemic treatment with CHEC-9 or
with related uncompetitive inhibitor CHEC-7, inhibited microglia
activation, demyelination and motor paralysis [9,10]. A central
question in these studies, and for the further development of
sPLA2 and other inflammation-targeted therapeutics, is to de-
termine the principal activity of these compounds, whether they
protect cells by inhibiting toxic inflammatory responses, or by
inhibiting cell death and thereby attenuating the inflammation. In
the present study, we utilized homogenous human SY5Y and HL-
60 cell lines. SY5Y neuroblastoma cells can be differentiated into
cells with morphological and biochemical characteristics of mature
neurons after stimulation with retinoic acid [18]. HL-60 leukemia
cells can be differentiated into macrophages by treatment with
phorbol 12-myristate 13-acetate (PMA) [19]. The results demon-
strate that this sPLA2 inhibitor independently promotes neuronal
cell survival, but not differentiation, and inhibits macrophage
differentiation but not survival. Given the well known effects of
sPLA2 enzymes on inflammation and cell survival, these dual
effects are what might be expected for an efficient enzyme
inhibitor and may explain the efficacy of the CHEC peptides when
applied to in vivo models.
Results
Inhibition of sPLA2 enzyme activity by CHEC-9
In order to confirm the CHEC-9 inhibition of enzyme activity,
we measured sPLA2 hydrolysis in the media of SY5Y and HL-60
cells. Macrophage differentiation was accompanied by a dramatic
increase in enzyme activity in both the vehicle (17506171%) and
CHEC-9 (10616195%) groups, compared with the undifferenti-
ated cells (100666.6%, Fig. 1A). CHEC-9 treatment at the
optimal concentration of 50 nM significantly reduced the sPLA2
activity in the medium after 4 days in culture (p=0.03). In the
SY5Y culture after two day’s exposure to serum deprivation,
similar reductions in sPLA2 activity were found with a single
treatment of CHEC-9: 1 nM- 48.5615.2%; 50 nM- 67.1611.1%;
vehicle- 100622.2%, (Fig. 1B). For the medium of these cells
however, individual values were much more variable and the effect
just missed significance (p=0.07).
Measurements of cPLA2 and iPLA2 activity in HL-60 cell
homogenates revealed no significant differences between un-
differentiated cells (cPLA2:100611.1%; iPLA2 10068.48%) and
differentiated cells (cPLA2: 93613.1%; iPLA2 127611.9%). No
inhibition of cPLA2 or iPLA2 activity was found by CHEC-9
treatment (cPLA2:102612.2%; iPLA2 133616.1%) (Fig. 1C, D),
suggesting the selectivity of this peptide under present culturing
conditions.
CHEC-9 promoted the survival of SY5Y neurons and
neuritic processes in response to medium change, serum
deprivation and macrophage conditioned medium
After 4days of differentiation with retinoic acid, SY5Y cells
exhibited their typical morphology of mature neurons with large
round nuclei and 3–5 neuritic processes. The stress induced by
medium change and serum deprivation led to a small loss of cells
(13.764.6%) and a more pronounced loss of neuritic processes
(40.267.4%). Dose-response analysis showed that CHEC-9 at
1 nM significantly increased cell and fiber numbers to near control
values, consistent with previous studies on the parent polypeptides
of CHEC-9 [12,13].
When SY5Y cells were subjected to medium from differentiated
HL-60 cells, there was also a significant loss of SY5Y cells by
28.963.04% (Fig. 2G) and loss of neuritic processes by
59.162.9% (Fig. 2C, F) compared with control media, obtained
either from SY5Y culture (Fig. 2A) or undifferentiated HL-60 cells
(Fig. 2B). Again, CHEC-9 treatment significantly improved the
survival of cells and processes (restoring the former to near control
level), but the effects required a higher concentration of 50 nM
than that supporting cells subjected to oxidative stress (Fig. 2D, G).
We also tested conditioned medium from HL-60 cultures that
were treated with CHEC-9 during differentiation. The medium
from these HL-60 cells also resulted in significant rescue of cells
and processes compared to vehicle-treated HL-60 conditioned
medium (Fig. 2F, G; also compare Fig. 2C to 2E).
In experiments to determine whether sPLA2 inhibition in-
fluence SY5Y cell differentiation, different concentrations of
CHEC-9 were added into SY5Y along with retinoic acid. There
was no effect on the differentiation of SY5Y cells in terms of the
process development, and only a slight protective effect during
differentiation (maximum of 7% increase at 50 nM of CHEC-9)
compared with vehicle culture (data not shown).
CHEC-9 treatment inhibited process development and
expression of CD36 of HL-60 cells during differentiation
without affecting viability
We found that PMA inhibited cell proliferation and induced
differentiation consistent with other studies using HL-60 cells as
a model of human macrophage differentiation [20]. Differentia-
tion includes cell adhesion spreading with process development,
expression of differentiation markers and cytokines, as well as
phagocytic activity, which are all characteristics of the macro-
phage phenotype [19]. For the present experiments, the optimal
CHEC-9 concentration (50 nM, determined by dose response)
Figure 1. Measurement of PLA2 activity. (A) HL-60 cells were
treated with 50 nM CHEC-9 or TBS vehicle for 4days with stimulation of
PMA. The large increase of sPLA2 activity after differentiation was
significantly attenuated by CHEC-9 treatment. (B) Differentiated SY5Y
neuronal cells were subjected to medium change and serum
deprivation for 2days. Compared with vehicle group, CHEC-9 treat-
ments at 1 and 50 nM both reduced sPLA2 activity, but this change just
missed significance (p=0.07). (C, D) cPLA2 and iPLA2 activity of HL-60
cell homogenates. There was no difference between the undiffentiated
and differntaited HL-60 cells. CHEC-9 treatment did not show inhibition
of the cPLA2 or iPLA2 activities.
doi:10.1371/journal.pone.0039257.g001
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days. HL-60 cells adhered to the culture plates, spread out, and
most grew processes (Fig. 3A). However, in the presence of
CHEC-9, the number of cells with processes decreased (Fig. 3B).
Instead there were large areas of small densely-stained HL-60
cells. Quantification of the cell number with process showed that
CHEC-9 treatment significantly decreased the number of cells
with processes compared with vehicle group (vehicle: 5963.9%,
CHEC-9: 34.461.6%, Fig. 3C). However, the total cell number of
HL-60 cells in two groups was not different, at least as measured
by the MTT assay, suggesting that CHEC-9 had no effects on the
survival of HL-60 cells (vehicle: 10061.1%; CHEC-9:
100.361.6%; Fig. 3D). Even when differentiated HL-60 cells
were subjected to medium change and serum deprivation, where
there was a loss of 33.263.6% of the cells, CHEC-9 did not show
protective effect on the survival of these cells (data not shown).
Upregulation of a number of differentiation markers including
CD36 have been documented as HL-60 cells differentiated into
macrophages [21]. Given the influence of the sPLA2 inhibition on
the morphology of HL-60 cells, we tested peptide effects on the
expression levels of CD36, a marker associated with activation and
phagocytosis. As shown in Figure 3 by immunostaining, the
differentiated HL-60 cells were all CD36 positive in both the
CHEC-9 and vehicle groups, but the fluorescent intensity was
greatly decreased by sPLA2 inhibition (Fig. 3E, F). Western-blot
results further confirmed the overall reduction of this protein
(Fig. 3G). Four days stimulation by PMA increased the expression
of CD36 in peptide and vehicle groups, but the intensity of CD36
bands was significantly attenuated to 71.267.1% by CHEC-9
treatment when compared with vehicle group (10068.4%).
(Fig. 3G)
CHEC-9 inhibited phagocytic activity and cytokine levels
of macrophages differentiated from HL-60 cells
Phagocytic activity is another characteristic of differentiated
macrophages. It has been reported PMA activated HL-60 cells are
capable of phagocytosis (including cannibalism) similar to activat-
ed native macrophages [22]. In order to test the influence of
sPLA2 inhibition on this activity of the HL-60 cells, we utilized
0.5 mm (diameter) fluorescent latex beads. Previous studies have
demonstrated the value of these for measurements of phagocytosis
[23]. In our study, most of the HL-60 derived macrophages in the
vehicle-treated group were labeled with red fluorescent beads after
24 hrs incubation (Fig. 4A). The intensity of single cell labeling,
which is proportional to the number of beads engulfed by the cells
was also high. Macrophage cultures that were treated with CHEC-
9 had a slightly lower percentage of cells containing any beads, but
individual cells contained about half as many beads as the vehicle
treated group (Fig. 4D). These results suggested CHEC-9 has the
most profound effects on the efficiency of phagocytosis, a result
consistent with the peptide’s effect on other aspects of differenti-
ation.
During the differentiation of HL-60 cells into macrophages, the
production of cytokines such as TNF-a and IL-6 has been
documented as an early response to PMA-induced activation [24].
These cytokines are two of the toxic mediators that are released by
macrophages in the inflammatory processes in various diseases
including neurodegenerative disorders [25]. Given the interaction
Figure 2. Protective effects of CHEC-9 on SY5Y cells. Retinoic acid differentiated SY5Y neuronal cells were subjected to different conditioned
media for 72 hrs. Cell process survival (A–F). Long and elaborated processes were seen in cultures that were subjected to control media either
from SY5Y cultures or undifferentiated HL-60 cultures (A, B). Dramatic degeneration of neuritic processes was found when SY5Y cells were subjected
to medium from differentiated HL-60 cultures (C). These degenerative changes were reversed by CHEC-9 (50 nM, D). Medium from HL-60 cultures -
pretreated with 50 nM CHEC-9 during differentiation, also preserved processes (E). (F) Quantification of the results. Cell viability (G). Both SY5Y
conditioned medium and undifferentiated HL-60 did not affect SY5Y survival, whereas the medium from differentiated HL-60 cells significantly
decreased viability. 50 nM CHEC-9 significantly restored the cell number to control level. Medium from HL-60 cultures-pretreated with 50 nM CHEC-9
during differentiation, also promoted cell survival. (* p,0.05, ** p,0.005).
doi:10.1371/journal.pone.0039257.g002
sPLA2 Has Dual Role in Neurodegeneration
PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e39257of sPLA2 with cytokines and the inhibition of HL-60 differenti-
ation by CHEC-9, we measured the secretion of those two
cytokines in the HL-60 medium. These studies were conducted
using dot blots because of the relatively low total protein in the
medium, and the attenuation of the specific cytokine signal during
processing for western analysis. Our results showed that sPLA2
inhibition decreased HL-60 cell secretion of TNF-a to
61.764.53% and IL-6 to 56.3610.7% when normalized to the
vehicle groups (TNF-a: 10068.86%; IL-6:10065.78%, Fig. 4E).
Discussion
The results confirmed the inhibition of sPLA2 activity by
CHEC-9 in both SY5Y and HL-60 cultures with no detectable
effects on the other major isoforms of PLA2 (cPLA2 and iPLA2).
And this inhibition provided direct neuroprotective effects toward
SY5Y neuronal cells in response to stressful stimuli induced by
serum deprivation or macrophage conditioned medium. Under
the conditions of cell stress used in these experiments, baseline cell
loss was relatively mild and processes degradation was more
pronounced. CHEC-9 inhibited both of these degenerative
changes. In cultures of HL-60 cells, sPLA2 enzyme inhibition
decreased the differentiation into macrophages induced by PMA
without affecting cell viability. In this case, CHEC-9 treatment
inhibited process development along with the expression of
differentiation/phagocytosis marker CD36, phagocytic ability
and the secretion of two prominent proinflammatory cytokines:
TNF-a and IL-6. The reduction of toxicity of conditioned medium
from CHEC-9 treated HL-60 cells further suggests that the
peptide’s influence on these cytokines contributes to the protection
of neuronal cells exposed to macrophage conditioned medium.
Therefore, this study suggests that sPLA2 inhibition has different
and distinct effects on these neuronal and immune cell
representatives, supporting the enzyme’s leading roles in survival
and inflammatory cascades that often characterize neurodegener-
ative disorders. The results further justify the view that sPLA2
enzymes would be a productive therapeutic target for these
disorders [7]. We also suggest that these results explain the potent
neuroprotective properties of CHEC-9 in vivo [9,10,14,15], where
the survival and anti-inflammatory effects of the peptide are likely
to be independent and additive. Furthermore, this study also
provides an in vitro testing system, using human cell lines to explore
the cellular targets of the potential neuroprotective/anti-inflam-
matory therapies.
sPLA2 inhibition via CHEC-9 promotes neuronal cell
survival directly
In our previous study, treatment with a longer peptide(YP-30),
or the over-expression of the full-length parent molecule DSEP
(diffusible survival evasion peptide) in neuronal cells, provided
remarkable survival promoting effects under conditions of stressful
stimuli such as medium change and serum deprivation or even
hydrogen peroxide exposure [12,13]. CHEC-9 is an internal
fragment of YP-30 and DSEP; and in this study it exerted a similar
protective effect toward SY5Y neuronal cells against stressful
stimuli. The inhibitory property of this peptide toward sPLA2
enzyme activity has been well studied in our previous work
[14,15]. The sPLA2 inhibition by this particular peptide sequence
(CHEASAAQC) appeared to be highly specific since inversion of
a single pair of amino acids (CHAESAAQC) eliminated the
inhibitory effect [15]. The uncompetitive and broad-spectrum
properties of this peptide may be advantageous with regard to in
vivo effectiveness [14,26]. In the present study, we confirmed the
inhibition of sPLA2 enzyme activity in SY5Y cultures, and these
results further support the suggestion that the sPLA2s are involved
in direct oxidant destruction of neurons [27,28]. Oxidative stress
can activate sPLA2 enzymes which in turn hydrolyze the
membrane phospholipids and impair the integrity of the mem-
brane, all leading to the death of the cell [2,3]. In addition, sPLA2
metabolism of phospholipids is a well-established source of reactive
oxidative species (ROS) especially during the production of
eicosanoids from arachidonic acid (AA). In metabolic processing
of AA by cyclooxygenases (COX) and lipoxygenases (LOX), free
radicals are produced as highly reactive intermediates or by-
products such as superoxide radicals (O2
2), or hydroxyl radicals(-
NOH) [29]. Additionally, the enzymatic activity of sPLA2 is directly
involved in the generation of ROS, mainly due to the hydrolysis of
Figure 3. Inhibition of differentiation of HL-60 cells by CHEC-9. HL-60 cells were treated with 50 nM CHEC-9 or TBS vehicle for 4days with
stimulation by PMA. HL-60 cells adhere to plate surface, flatten out and grow processes (A). CHEC-9 treatment decreased the number of cells with
process (B). Quantification of Coommassie blue staining (C). CHEC-9 did not affect viability of the cells (D). Immunostaining for CD36 showed that the
fluorescent intensity of CHEC-9 group was decreased compared with vehicle group (E, F). This observation was supported by western analysis (G).
Quantification was by normalization to GAPDH bands. (* p,0.05, ** p,0.005).
doi:10.1371/journal.pone.0039257.g003
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mitochondrial respiratory chain [30,31]. Treatment with sPLA2
inhibitor CHEC-9 appears to interfere with the above processes
explaining the survival promoting effects of this peptide. In-
terestingly, despite this survival-promoting activity in neuronal
cells, the peptide did not show protection toward HL-60 cells. This
result is consistent with previous studies that sPLA2-IIA had no
toxic effects on guinea pig alveolar macrophages, human blood
monocytes, HL-60 and U937 monocytic cell lines [32–34]. It may
be that cells which produced significant quantities of proinflam-
matory and toxic mediators as scavengers and disinfectants are
immune to the autocrine effects of these mediators.
sPLA2 inhibition via CHEC-9 is also anti-inflammatory
In addition to reactive oxygen species, proinflammatory
cytokines (such as TNF-a and IL-6), lytic enzymes (such as
sPLA2), lipids mediators (such as lysophospholipids) are among the
most potent inflammatory mediators that are released by activated
immune cells after neural trauma or during the progression of
CNS neurodegenerative disorders [35–37]. Although the principal
function of these activated immune cells is the destruction of
foreign organisms and phagocytosis of degenerating elements,
activation of these cells to perform these functions also means
collateral damages: the secretion of toxic mediators that can kill
non-degenerating bystander cells and axons of passage, and
thereby exaggerate functional deficits that result from lesions
[38,39]. In this study, we inhibited sPLA2 enzyme activity and the
secretion of proinflammatory mediators from HL-60 cells;
protected SY5Y cells from degeneration after exposure to the
macrophage conditioned medium. This medium is much less toxic
when the cells are pretreated with CHEC-9, although it is possible
that CHEC-9 that was originally added to HL-60 cells was carried
over to SY5Y culture when we transferred the conditioned
medium. However, based on the finding of the strong influence of
CHEC-9 on HL-60 differentiation, we conclude that indirect
effects via inhibition of HL-60 cell functions and secretions must at
least contribute to the protective activity of the peptides observed
after medium transfer. In addition, there is abundant experimental
support for interaction of cytokines with sPLA2 enzymes including
the existence of a positive feedback loop in several cell types. For
example, sPLA2-IIA mRNA and protein expression and PLA2
activity were all increased after exposure of astrocytes cultures to
proinflammatory cytokines (TNF-a, interleukin-1b and interferon
c) [11,40]. The bioactive downstream PLA2 products, such as
linoleic acid, lysophosphatidylcholine and prostaglandin E2
contributed to the inflammatory cascade by upregulation of
inflammatory cytokines such as TNF-a and IL-6 in macrophages
[41]; prostaglandin E2 and TNF-a also have synergic effects on
promoting the activation of transcription factor NF kappaB [42].
The activation of NF kappaB by TNF-a in keratinocytes is
strongly reduced by a specific sPLA2 inhibitor. This result suggests
that the downstream effects of TNF-a depend at least in part on
sPLA2 [43].
The present results also support the suggestion that sPLA2
enzymes contribute to macrophage differentiation and activity.
Exogenous snake venom PLA2 significantly potentiated the
differentiation of HL-60 cells to macrophages with the presence
of PMA [44]. Similar effects were also observed with the products
of PLA2 hydrolysis activity: lysophosphatidylcholine and free fatty
acids such as linoleic acid [21]. These findings, together with our
results, suggest that activation of sPLA2 may be intimately related
to the signal transduction pathway during HL-60 differentiation.
As shown in the present study, the production and/or release of
cytokine TNF-a was attenuated as a result of sPLA2 inhibition.
The decreased TNF-a level also helps to explain CHEC-9 actions
because it has been reported that TNF-a regulated macrophage
differentiation of HL-60 cells in an autocrine manner [45].
Another crucial function of macrophages is the capacity to capture
exogenous antigens, that is, phagocytic activity. We found that
sPLA2 inhibition by CHEC-9 significantly altered the processes of
phagocytosis and the expression of one phagocytic receptor CD36
on HL-60 cells. These findings are consistent with previous studies.
When sPLA2-IIa was added to THP cells–another human
monocyte cell line, their endocytic capacity was significantly
enhanced [32]. In addition, sPLA2-V was found to directly
regulate phagosome formation in mouse macrophages [33,34]. In
addition to these previous studies, the present work adds another
line of evidence that strongly supports the crucial roles of sPLA2 in
innate immunity and inflammation.
Figure 4. Phagocytosis activity and cytokine levels of macro-
phages differentiated from HL-60 cells. Most macrophages in
vehicle group were labeled with red beads and the intensity of beads
was high (A). Macrophages treated with CHEC-9 engulfed significantly
fewer beads after 4 days differentiation and resulted in a lower
percentage of cells containing beads. Quantification of the results (C,
D). Decreased expression of TNF-a and IL-6 by 50–60% was found in the
cell medium of CHEC-9 treated group (E). (** p,0.005).
doi:10.1371/journal.pone.0039257.g004
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for the study of neurodegeneration and monocyte/macrophage
differentiation respectively [18,19]. In the present study, using
isolated cells, we tested the effects of the peptide on the two major
representatives of the neurodegeneration: neuronal and immune
cell. Then, by using conditioned media, one mode of neuronal-
inflammatory cell interactions was investigated. It is possible that
this method can be adapted for high-throughput screening of
drugs targeting a variety of neurodegenerative disorders.
In summary, we designed in vitro tests to indentify the cellular
targets of sPLA2 enzymes, and with this testing system, we
provided experimental evidence that sPLA2 inhibitor CHEC-9
had differential effects on neuronal and immune cells. In addition
to the direct protection of neuronal cells, this peptide can
independently inhibit immune cell responses and therefore also
protect the cells indirectly. Since there is lack of effective
treatments for most neurological disorders, the ability to explore
these different modes of neuronal protection in vitro may be of
great interest for the design of such therapies.
Materials and Methods
Peptide preparation
CHEC-9 (CHEASAAQC) was synthesized as a linear peptide
by Celtek, Inc. The peptide was cross-linked for optimal stability
and effectiveness in tris-buffered saline (TBS, pH 7.8) at 0.25 mg/
ml overnight. Free sulfhydryls were measured using Ellman’s
reagent and were undetectable after cross-linking, which was
further verified by electrospray mass spectrometry as in previous
studies [14].
Cell culture and differentiation
The human SY5Y neuroblastoma cell line (American Type
Culture Collection, Manassas, VA) [18] and human HL-60
myeloid leukemia cell line (American Type Culture Collection,
Manassas, VA) [19] were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) and RPMI 1640 medium (Mediatech, Mana-
ssas, VA) respectively, supplemented with 10% fetal bovine serum
(FBS), 2 mM L-glutamine and antibiotics (penicillin 100 U/ml
and streptomycin 100 g/ml) at 37uC in a saturated humidity
atmosphere containing 95% air and 5% CO2. Treatment and
medium change were every other day.
SY5Y cells were plated at the density of 1610
5 cells/ml and
were differentiated into neuronal phenotype with 15 mM all-trans-
retinoic acid (Sigma, St. Louis, MO) for 4 days. Differentiated
SY5Y cells were subjected to rapid change to serum free medium
or exposed to conditioned medium obtained from differentiated
HL-60 cultures. Medium from undifferentiated HL-60 cultures or
SY5Y cultures served as controls. Forty-eight to seventy-two hours
later, cell and neurite survival were examined. In some experi-
ment, SY5Y cells were treated with CHEC-9 or TBS vehicle
during the differentiation period.
HL-60 cells were cultured at a density of 1610
6 cells/ml and
differentiated into macrophages by treatment with 20 nM phorbol
12-myristate 13-acetate (PMA). TBS vehicle or CHEC-9 was
added to HL-60 cells to study the effects of sPLA2 inhibition in
different aspects of macrophage differentiation. In other experi-
ments designed to mimic treatment of SY5Y cells, differentiated
HL-60 cells were treated with CHEC-9 or vehicle after medium
change and serum deprivation. For cell viability assay, cells were
cultured in 96-well plates. For the analysis of neurite survival/
growth, CD36 marker expression and cell morphology, cells were
plated in eight-well Lab-Tek chamber plastic slides (Thermo,
Rochester, NY). All the plates and slides were previously coated
with poly-L-lysine.
PLA2 enzyme activity assay
Culture media from SY5Y and HL-60 cells were tested for
sPLA2 enzyme activity by procedures similar to those described
[10]. One-hundred microliter of cell-free medium was reacted
with 200 mM 1,2-bis (heptanoylthio) glycerol-phosphocholine in
a reaction buffer consisting of 50 mM tris, 0.1 M NaCl (pH=7.4),
1 mM DTNB (Ellman’s reagent). The reaction was initiated by the
addition of CaCl2 (final concentration 2.5 mM). Reaction rates
were determined with a Deltasoft (Princeton, NJ) supported ELX
808 reader (Biotek, Burlington, VT) and the rate of product
formation was measured for 40 minute and calculated relative to
control conditions. Cell homogenates from HL-60 cultures were
tested for cPLA2 activity with minor modifications of manufac-
tures suggested protocol(Cayman chemical, Ann Arbor, MI) and
iPLA2 activity by procedures previously described [41]. Briefly,
the cells were collected using cell scraper, homogenized and
centrifuged at 20 000 g for 30 min at 4uC. The sPLA2 activity was
removed from those samples using membrane filter with
a molecular weight cut-off of 30,000 (Millipore, Danvers, MA).
Fifty microliter of cell-free supernatant was reacted with 300 mM
2-deoxy-2-thio arachidonoyl glycerol-phosphocholine in the same
buffer described above. CaCl2 was added to cPLA2 assays in the
presence of iPLA2 inhibitor bromoenol lactone, whereas iPLA2
assay was calcium free. The overall reaction was determined as
described above, and calculated relative to the undifferentiated
HL-60 cultures.
Cell viability assay
Cell viability assays were carried out using the MTT assay kit
(Life Technologies, Grand Island, NY) according to manufac-
turer’s instructions. A MTT standard curve was also obtained to
make sure the measurements in those experiments fall into the
linear range. Values obtained in different conditions were
normalized to control cultures.
Whole cell staining and neuritic process analysis
TUJ1 staining was carried out to examine the survival of
neurites in SY5Y cells. Briefly, the cells were fixed for 20 min in
buffered 2% paraformaldehyde and processed for immunostaining
with TUJ1 primary antibody to neuronal specific tubulin (isotype
III, Covance, Princeton, NJ) and HRP conjugated secondary
antibody. Systematically defined fields were photographed and
neurites were quantified by counting the number of fibers that
intersect the grid lines which were overlaid in ImageJ.
After 4 days of differentiation, HL-60 cells in TBS vehicle or
CHEC-9 groups were fixed with 2% paraformaldehyde and
stained with Coommassie blue solution (0.2% Brilliant Blue in
20% methanol, 0.5% acetic acid). The percentage of cells with
process was calculated in three fields of each well. For this and all
other in vitro experiments, at least two independent sets of cell
cultures were examined by experimentally blind observers and
each experimental condition was analyzed in quadruplicate
cultures.
CD36 immunostaining and western blot analysis
HL-60 cells were fixed and processed for staining with antibody
to macrophage differentiation marker CD36 (Santa Cruz Biotech,
Santa Cruz, CA) and FITC- conjugated secondary antibody.
Western-blots from lysed and homogenized HL-60 cells were
prepared as described previously [46,47], using CD36 and
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negative control. Thirty microgram of protein were subjected to
Tris–HCl SDS–PAGE and transferred to nitrocellulose membrane
(Bio-Rad Laboratories, Hercules, CA). After incubation with
HRP-conjugated secondary antibody, the membranes were
processed for ECL immunodetection and whole band analysis
was conducted with Image J (NIH). Band intensities were
normalized to GAPDH loading control. Samples were derived
from at least three different cultures and, each sample was
analyzed 3–4 times with peptide-treated and control treated
samples run side by side.
Measurement of TNF-a and IL-6
Cell-free medium of HL-60 cells in different groups was
collected and tested using dot-blotting. Briefly, the protein
concentration of those samples was measured and 1 mlo f( 4mg/
ml, 2 mg/mlo r1mg/ml) samples were dotted onto a nitrocellulose
membrane and air-dried for two hours. The membranes were
blocked and stained with antibodies to TNF-a and IL-6 (Santa
Cruz Biotech, Santa Cruz, CA) and the protein dots were detected
with ECL. Negative control was incubated with secondary
antibody only to detect non-specific signals. The dots densities
were analyzed as above.
Phagocytosis assay
Differentiated HL-60 cells were incubated for 24 hours with
sterilized 0.5 mm (diameter) fluorescent latex beads (Sigma, St.
Louis, MO) at the concentration of 6610
6/well. Thereafter, the
cells were fixed, reacted with a b-actin antibody (Sigma, St. Louis,
MO) define the cell outline and mounted with DAPI-containing
medium. The phagocytic ability of cells were analyzed at least
three fields of each culture by calculating the percentage of bead
positive cells and the intensity of beads in individual cells using
ImageJ.
Statistical analysis
The data were expressed as mean 6 SEM. Statistical
significance between two groups was assessed with an analysis of
variance followed by Student’s t-test. Statistical significance
between multiple groups was performed using a one-way analysis
of variance (ANOVA). When ANOVA showed a significant
difference, an LSD multiple comparisons post-hoc test was
performed. A value of p,0.05 was considered significant.
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